NASDAQ: CELCCelcuity Inc Stock
$107.95+3.46 (+3.31%)
Updated Jul 2, 2026
CELC Price
$107.95
Fair Value Price
-$0.56
Market Cap
$5.26B
52 Week Low
$13.16
52 Week High
$151.02
P/E
-27.61x
P/B
98.35x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$192.89M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
6.66
Operating Cash Flow
-$172M
Beta
0.91
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CELC Overview
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CELC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CELC
Ranked#265 of 463
Ranked#265 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important CELC news, forecast changes, insider trades & much more!
CELC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CELC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CELC ($107.95) is overvalued by 19,212.6% relative to our estimate of its Fair Value price of -$0.56 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CELC ($107.95) is not significantly undervalued (19,212.6%) relative to our estimate of its Fair Value price of -$0.56 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CELC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CELC due diligence checks available for Premium users.
Valuation
CELC fair value
Fair Value of CELC stock based on Discounted Cash Flow (DCF)
Price
$107.95
Fair Value
-$0.56
Undervalued by
19,212.60%
CELC ($107.95) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CELC ($107.95) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CELC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CELC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-27.61x
Industry
17.59x
Market
8.54x
CELC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
98.35x
Industry
5.6x
CELC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CELC's financial health
Profit margin
Revenue
$0.0
Net Income
-$52.8M
Profit Margin
0%
CELC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$410.2M
Liabilities
$356.6M
Debt to equity
6.66
CELC's short-term assets ($408.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CELC's short-term assets ($408.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CELC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CELC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$55.1M
Investing
$34.5M
Financing
$34.0k
CELC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CELC vs Biotech Stocks
Celcuity Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.